Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00005084
Status:
UNKNOWN
Last Update Posted:
2013-12-18
First Post:
2000-04-06
Brief Title:
Magnetic Resonance Imaging in Treating Children With Progressive Low-Grade Astrocytoma
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Pediatric Low Grade Astrocytoma Treatment Guidance
Status:
UNKNOWN
Status Verified Date:
2008-02
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE New imaging procedures such as magnetic resonance imaging may improve the ability to determine the growth rate of progressive astrocytoma
PURPOSE Phase II trial to study the effectiveness of magnetic resonance imaging in treating children who have progressive low-grade astrocytoma
PURPOSE Phase II trial to study the effectiveness of magnetic resonance imaging in treating children who have progressive low-grade astrocytoma
Detailed Description:
OBJECTIVES I Determine if tumor growth rate can be decreased by targeting areas of increased choline activity as measured by magnetic resonance spectroscopic imaging in pediatric patients with progressive low grade astrocytoma treated with surgical resection andor focal radiotherapy II Improve the quality of life without use of aggressive surgery or radiotherapy in this patient population
OUTLINE Patients undergo magnetic resonance spectroscopic imaging MRSI over 60 minutes prior to surgery andor radiotherapy Patients are assigned to one of two treatment arms based on tumor accessibility and may crossover to either arm Arm I Patients undergo conventional surgery Arm II Patients with inaccessible tumors undergo focal radiotherapy Following surgery andor radiotherapy patients are followed every 4 months for up to 2 years with MRSI or MRI for tumor response and growth
PROJECTED ACCRUAL A total of 24 patients will be accrued for this study over 2 years
OUTLINE Patients undergo magnetic resonance spectroscopic imaging MRSI over 60 minutes prior to surgery andor radiotherapy Patients are assigned to one of two treatment arms based on tumor accessibility and may crossover to either arm Arm I Patients undergo conventional surgery Arm II Patients with inaccessible tumors undergo focal radiotherapy Following surgery andor radiotherapy patients are followed every 4 months for up to 2 years with MRSI or MRI for tumor response and growth
PROJECTED ACCRUAL A total of 24 patients will be accrued for this study over 2 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G00-1728 | None | None | None |
| UCLA-9702077 | None | None | None |